A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Phase 1/2 Terminated 27 enrolled AVEO Pharmaceuticals, Inc. AstraZeneca · collab

NaSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.

Timeline

Start: 2019-09-30
Primary completion: 2023-04-04
Completion: 2023-04-04

Publications

Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncol. 2022 Dec;18(40):4465-4471. doi: 10.2217/fon-2022-0844. Epub 2023 Mar 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	—
Subject	Tivozanib	Small molecule	1 mg	—

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Summary

Timeline

Publications

Drugs

Indications